Factors Affecting Discontinuation of Alendronate Treatment in Postmenopausal Japanese Women With Osteoporosis  by Iwamoto, Jun et al.
J Chin Med Assoc • December 2009 • Vol 72 • No 12 619
Introduction
The efficacy of bisphosphonates such as alendronate
in the treatment of osteoporosis in postmenopausal
women has been established. According to global data,
alendronate treatment increases lumbar and hip bone
mineral density (BMD) and decreases the incidence of
vertebral and hip fractures.1,2 Japanese data show that
alendronate treatment increases lumbar and hip BMD
and prevents vertebral fractures.3–6
To diagnose and treat osteoporosis, an assessment of
BMD is required. Dual energy X-ray absorptiometry
is utilized to measure lumbar, femoral neck, and fore-
arm BMD, and computed X-ray densitometry is used
to measure metacarpal BMD. Because dual energy 
X-ray absorptiometry machines are very expensive,
they are not always available. Therefore, many Japanese
hospitals and clinics measure metacarpal BMD using
computed X-ray densitometry to diagnose osteopo-
rosis and to monitor the efficacy of medication on
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osteoporosis treatment. The long-term adherence of
patients has been the main challenge to effective treat-
ment using bisphosphonates. However, there are few
reports of the long-term effects of alendronate on
metacarpal BMD, and furthermore, the factors affect-
ing the adherence of patients to alendronate treat-
ment have not been established in postmenopausal
Japanese women with osteoporosis. The purposes of
this cohort study were to investigate the 3-year 
outcome of alendronate treatment in postmenopausal
Japanese women with osteoporosis and to identify the




Seventy-two postmenopausal Japanese women with
osteoporosis,7,8 aged 57–85 years, were recruited at
Yahata Clinic (Tokyo, Japan) from October 2001 to
September 2002. Using the Japanese criteria for osteo-
porosis in women,7,8 patients whose BMD was either
< 70% of the young adult mean or 70–80% of the
young adult mean together with a history of osteo-
porotic fractures were diagnosed as having osteoporo-
sis. Inclusion criteria were postmenopausal women with
osteoporosis with or without a history of osteoporotic
fractures. Exclusion criteria were histories of reflux
esophagitis, gastric or duodenal ulcer, gastrectomy, or
bone diseases including primary hyperparathyroidism,
hyperthyroidism, Cushing’s syndrome, multiple mye-
loma, rheumatoid arthritis, and osteogenesis imper-
fecta. Women who had ever taken medication known
to affect bone metabolism were also excluded. All sub-
jects participated in a 3-year trial of alendronate treat-
ment (5 mg daily). This dose is recognized as effective
for Japanese patients with osteoporosis.3–6 All subjects
were given a pamphlet instructing them to take 800mg
of calcium daily through food intake. Table 1 shows the
characteristics of the study subjects. Informed consent
was obtained from all subjects.
Subjects were monitored and followed-up with
pre-and post-treatment examinations that included 
a medical history, physical examination, radiographic
examination of the thoracic and lumbar spine, meta-
carpal BMD measurement, and blood and urine bio-
chemical tests. Assessment of vertebral fractures on
radiographs and metacarpal BMD measurement were
performed as described below. Metacarpal BMD mea-
surement was assessed at baseline and once every year
after that. Serum calcium, phosphorus, and alkaline
phosphatase (ALP) levels were measured with standard
laboratory techniques at baseline and once every year
after that. Urinary cross-linked N-terminal telopep-
tides of type I collagen (NTX) level was measured by
enzyme-linked immunosorbent assay at baseline and
then only once, 3 months after the start of treatment.
A general practitioner (GP) at Yahata Clinic carried out
the treatments. All participants met the GP at least
once a month during the 3-year treatment period as
long as they continued alendronate treatment. The
ethics committee of Yahata Clinic approved the proto-
col for this study.
Assessment of vertebral fractures
Radiographs of the thoracic and lumbar spine were
taken to find evidence for vertebral fractures. Vertebral
fracture was defined according to the vertebral height
obtained from lateral X-ray films based on the Japanese
criteria.7,8 Briefly, vertebral height was measured at the
anterior (A), central (C), and posterior (P) parts of the
vertebral body, and the presence of a vertebral fracture
was confirmed when: (1) there was more than 20%
reduction of vertebral height (A, C, and P) compared
with the neighboring vertebrae; (2) C/A or C/P was
less than 0.8; or (3) A/P was less than 0.75. Assessment
of vertebral fractures was performed for T4 to L4.
Measurement of metacarpal BMD
An anteroposterior view radiograph of bilateral hands
was taken of each subject using an aluminum step wedge
(20 steps, 1 mm per step) as a standard. The BMD of
the middle portion of the second metacarpus of the
nondominant hand was measured with a computed
X-ray densitometer (Teijin, Tokyo, Japan). The den-
sitometer calculated BMD based on the graduations
Table 1. Characteristics of all 72 study subjects*
Age (yr) 73.4 ± 5.8 (58–85)
Height (m) 1.47 ± 0.06 (1.34–1.60)
Body weight (kg) 47.5 ± 7.0 (34–65)
Body mass index (kg/m2) 21.8 ± 2.4 (16.9–27.4)
Years since menopause 22.7 ± 5.6 (10–36)
BMD (mm Al) 1.88 ± 0.24 (1.07–2.19)
BMD % of YAM (%) 69 ± 9 (39–79)
Serum calcium (mg/dL) 8.9 ± 0.3 (8.3–9.8)
Serum phosphorus (mg/dL) 3.6 ± 0.6 (2.4–5.6)
Serum ALP (IU/L) 234 ± 94 (98–482)
Urinary NTX (nmol 69.0 ± 31.7 (35.0–160.3)
BCE/mmol Cr)
Vertebral fractures (n) 2.3 ± 2.3 (0–8)
*Data are presented as mean ± standard deviation (range). BMD = bone min-
eral density; mm Al = aluminum equivalent; YAM = young adult mean;
ALP = alkaline phosphatase; NTX = cross-linked N-terminal telopeptides of
type I collagen; nmol BCE/mmol Cr = bone collagen equivalent per mmol of
creatinine.
on the aluminum step wedge, and BMD was expressed
as the thickness of the aluminum equivalent (mm Al)
with the same X-ray absorption. In this measurement,
the coefficients of variation (100 × standard deviation/
mean) for (1) intraobserver error, based on 10 con-
secutive measurements by 5 people, (2) daily change
error, based on measurements performed on 10 con-
secutive days, and (3) X-ray picturing error, based on
10 exposures, were all within 1.3–3.8%.
Statistical analysis
Data are expressed as mean ± standard deviation. The
significance of longitudinal changes in metacarpal
BMD, and serum calcium, phosphorus, and ALP and
urinary NTX levels was determined by one-way analy-
sis of variance with repeated measurements. Compar-
isons of the characteristics and percent changes in
urinary NTX level at 3 months between subjects who
continued and discontinued alendronate treatment
were performed using an unpaired t test. Factors con-
tributing to the discontinuation of alendronate treat-
ment were identified by logistic regression analysis.
The independent variables were age, height, body
weight, body mass index, years since menopause, BMD,
% of young adult mean of BMD, serum calcium, phos-
phorus, and ALP levels, urinary NTX level, and the
number of prevalent vertebral fractures. The depend-
ent variables were continuation (input 0) and discon-
tinuation (input 1) of alendronate treatment. Odds
ratios and 95% confidence intervals were calculated.
All statistical analyses were performed using the Excel
Analysis 2008 Software (Social Survey Research Infor-
mation Co., Ltd., Tokyo, Japan). A significance level
of p < 0.05 was used for all comparisons.
Results
Discontinuation of alendronate treatment
During the 3-year period, 14 patients (19.4%) dropped
out of the trial; 3 patients dropped out within 3 months,
and 11 within 6 months. The reasons for dropping out
were: side effects (diarrhea [n = 1], gastric symptoms
[n = 9], and inflammation of the mouth [n = 1]); or
non-compliance (n = 3). Logistic regression analysis
showed that the number of prevalent vertebral fractures
was a significant factor (odds ratio, 1.57; 95% confi-
dence interval, 1.08–2.30; p = 0.020) contributing to
the discontinuation of alendronate treatment due to
the reasons listed above (Table 2).
Table 3 shows the characteristics of both patients
who continued and discontinued alendronate treatment.
Only the number of vertebral fractures was greater in
patients who continued alendronate treatment than
in those who discontinued the treatment (2.0 ± 2.2 vs.
3.6 ± 2.2, respectively).
Changes in BMD, serum calcium, phosphorus
and ALP, and urinary NTX levels
Table 4 shows the longitudinal changes in metacarpal
BMD, serum calcium, phosphorus and ALP, and uri-
nary NTX levels. In 58 patients who continued the
treatment for 3 years, the mean percentage change in
urinary NTX level at 3 months was – 44.1% compared
with the baseline (p < 0.0001 by one-way analysis of
variance with repeated measurements); the mean per-
centage change in serum ALP level compared with
the baseline was –11.6% at 1 year, –11.8% at 2 years,
and –12.5% at 3 years (p < 0.0001 by one-way analysis
of variance with repeated measurements). However,
the mean percentage change in metacarpal BMD com-
pared with the baseline was + 0.5% at 1 year, + 0.0% 
at 2 years, and + 0.9% at 3 years with no significant
changes (p = 0.777 by one-way analysis of variance
with repeated measurements). Although serum cal-
cium level significantly decreased (p = 0.005 by one-
way analysis of variance with repeated measurements),
serum phosphorus level did not significantly change
(p=0.058 by one-way analysis of variance with repeated
measurements).
Urinary NTX data at 3 months were available for
11 patients who discontinued alendronate treatment
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Table 2. Factors affecting discontinuation of alendronate 
treatment*
OR 95% CI p
Age (yr) 1.35 0.99–1.85 0.060
Height (m) 0.82 0.21–3.27 0.779
Body weight (kg) 1.51 0.18–12.56 0.704
Body mass index 0.41 0.00–42.24 0.705
(kg/m2)
Years since menopause 0.80 0.59–1.10 0.168
BMD (mm Al) > 0.99 < 0.01– > 0.99 0.206
%YAM of BMD (%) 0.17 0.01–2.60 0.200
Serum calcium (mg/dL) 10.64 0.26–428.20 0.210
Serum phosphorus 2.18 0.52–9.07 0.285
(mg/dL)
Serum ALP (IU/L) 0.99 0.98–1.00 0.138
Urinary NTX 0.98 0.95–1.01 0.273
(nmol BCE/mmol Cr)
Vertebral fractures (n) 1.57 1.08–2.30 0.020
*Logistic regression analysis was used to identify factors affecting the 
discontinuation of alendronate treatment. OR = odds ratio; CI = confidence
interval; BMD = bone mineral density; mm Al = aluminum equivalent; YAM =
young adult mean; ALP = alkaline phosphatase; NTX = cross-linked N-terminal
telopeptides of type I collagen; nmol BCE/mmol Cr = bone collagen equivalent
per mmol of creatinine.
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within 6 months. The mean percent change in urinary
NTX level at 3 months compared with the baseline 
in those patients was −40.2% (p < 0.0001 by one-way
analysis of variance with repeated measurements).
However, the unpaired t test showed that there was
no significant difference in changes to this parameter
between patients who continued and discontinued
alendronate treatment (p = 0.614).
Discussion
This cohort study showed that alendronate treat-
ment decreased urinary NTX and serum ALP levels,
and maintained metacarpal BMD in postmenopausal
Japanese women with osteoporosis. The majority of
patients adhered well to alendronate treatment in our
clinic. The number of prevalent vertebral fractures
was a significant factor affecting the discontinuation
of alendronate treatment due to side effects and 
non-compliance.
Choices in osteoporosis treatment usually derive
from evidence-based medicine and the results of sys-
tematic reviews and meta-analyses are considered crit-
ical evidence when determining treatment type. Such
meta-analysis studies have shown that alendronate is
an efficacious agent for reducing the risk of vertebral,
nonvertebral, and hip fractures in postmenopausal
osteoporotic women. The risk reduction rate is 48%,
49%, and 55%, respectively.9–11 For this reason, we
chose alendronate for our patients. Had parathyroid
hormone been available in Japan at the time our study
was carried out, we might have considered this option,
but it was not.
The response of BMD to alendronate appears to
differ among skeletal sites. Tucci et al12 have reported
that the effect of alendronate on BMD in postmeno-
pausal women with osteoporosis is greater in the lumbar
Table 3. Comparison of characteristics between subjects who continued and discontinued alendronate treatment*
Continued (n = 58) Discontinued (n = 14) p
Age (yr) 72.8 ± 6.1 75.9 ± 3.9 0.074
Height (m) 1.47 ± 0.06 1.48 ± 0.06 0.752
Body weight (kg) 47.4 ± 6.8 47.9 ± 8.2 0.846
Body mass index (kg/m2) 21.8 ± 2.3 21.8 ± 2.8 0.988
Years since menopause 22.4 ± 5.8 23.9 ± 4.6 0.354
BMD (mm Al) 1.88 ± 0.24 1.88 ± 0.25 0.970
BMD % of YAM (%) 68.5 ± 8.5 68.7 ± 9.1 0.954
Serum calcium (mg/dL) 8.9 ± 0.3 9.0 ± 0.3 0.456
Serum phosphorus (mg/dL) 3.6 ± 0.6 3.6 ± 0.7 0.873
Serum ALP (IU/L) 243 ± 93 198 ± 93 0.110
Urinary NTX (nmol BCE/mmol Cr) 70.7 ± 31.5 62.3 ± 32.5 0.375
Vertebral fractures (n) 2.0 ± 2.2 3.6 ± 2.2 0.016
*Data are presented as mean ± standard deviation. BMD = bone mineral density; mm Al = aluminum equivalent; YAM = young adult mean; ALP = alkaline 
phosphatase; NTX = cross-linked N-terminal telopeptides of type I collagen; nmol BCE/mmol Cr = bone collagen equivalent per mmol of creatinine.
Table 4. Changes in BMD and biochemical markers*
Baseline Mo 3 Yr 1 Yr 2 Yr 3 One-way ANOVA
BMD (mm Al) 1.88 ± 0.23 1.89 ± 0.25 1.88 ± 0.25 1.89 ± 0.23 0.777
(% change from baseline) (0.5 ± 4.8) (0.0 ± 3.8) (0.9 ± 7.1)
Serum calcium (mg/dL) 9.1 ± 0.5 8.9 ± 0.4 8.8 ± 0.4 8.9 ± 0.4 0.005
(% change from baseline) (–1.8 ± 5.2) (–2.0 ± 5.6) (–1.1 ± 6.0)
Serum phosphorus (mg/dL) 3.6 ± 0.6 3.7 ± 0.7 3.4 ± 0.5 3.5 ± 0.5 0.058
(% change from baseline) (5.7 ± 22.0) (–3.3 ± 11.3) (0.0 ± 19.7)
Serum ALP (IU/L) 243 ± 93 208 ± 66 206 ± 65 201 ± 57 < 0.0001
(% change from baseline) (–11.6 ± 16.4) (–11.8 ± 17.1) (–12.5 ± 19.1)
Urinary NTX (nmol BCE/mmol Cr) 70.7 ± 31.5 36.7 ± 16.1 < 0.0001
(% change from baseline) (–44.1 ± 23.6)
*Data are presented as mean ± standard deviation and one-way ANOVA with repeated measurements was used to determine the significance of longitudinal
changes in BMD and biochemical markers. BMD = bone mineral density; mm Al = aluminum equivalent; ALP = alkaline phosphatase; NTX = cross-linked 
N-terminal telopeptides of type I collagen; nmol BCE/mmol Cr = bone collagen equivalent per mmol of creatinine.
spine than in the femoral neck, and seems to be least
in the forearm. The mean improvement in BMD from
baseline after 3 years of treatment with alendronate
(10 mg daily) was 9.59% in the lumbar spine, 4.66%
in the femoral neck, 7.38% in the femoral trochanter,
4.97% in the total hip, and 0.32% in the forearm (distal
third of the forearm). In our study, the mean improve-
ment in metacarpal and lumbar BMD after 3 years of
treatment with alendronate was 0.9%. This change
was smaller than those observed in other skeletal sites.
Because the normal range of urinary NTX level in
Japanese women is 9.3–54.3 nmol of bone collagen
equivalent per mmol of creatinine,13 our patients were
considered to show high bone turnover osteoporosis
(mean urinary NTX level: 70.7 nmol of bone collagen
equivalent per mmol of creatinine). Alendronate treat-
ment successfully reduced urinary NTX levels by 44.1%
at 3 months, a greater reduction than the minimum
significant change (35%). Serum ALP was less sensitive
to alendronate treatment than urinary NTX. However,
alendronate treatment failed to increase metacarpal
BMD in postmenopausal women with osteoporosis.
The minimal effect of alendronate treatment on BMD
in the metacarpus might be associated with the fol-
lowing factors: the type of bone (appendicular or axial
bone), the ratio of cancellous to cortical bone, and
the low reproducibility of BMD measurements.14 If
the lumbar spine had been evaluated as a BMD mea-
surement site, patients might have experienced an
increase in BMD.14
Adherence of our patients to alendronate treat-
ment was better than previously reported.15,16 One
reason for this may be that most of the patients came
to our outpatient clinic once or twice a week to
undergo physical therapies for symptoms related to
osteoporosis, spondylosis, and osteoarthritis, and were
encouraged by the GP to continue treatment. Another
reason may have been that our informed consent docu-
mentation also encouraged patients to continue treat-
ment by stating the following: (1) treatment with
bisphosphonates such as alendronate is recommended
because high bone turnover in postmenopausal women
with osteoporosis can increase the incidence of verte-
bral fractures, resulting in disability and mortality; (2)
long-term treatment with alendronate may be effective
in preventing osteoporotic fractures including verte-
bral and hip fractures that might occur in later life
(this is supported by a recent report);17 (3) reducing
bone turnover (as especially indicated by a reduction
in urinary NTX levels) could be more important than
increasing BMD to prevent vertebral fractures;18–20
(4) patients should take the medicine according to
our instructions to avoid serious side effects and to
achieve a satisfactory outcome. In addition, the method
for taking the medicine was explained (with the aid of
a pamphlet) by both a doctor and a pharmacist. Thus,
education and communication are important to improve
patient compliance. However, the satisfactory results
of repeated measurements of urinary NTX level might
not contribute to continuation of alendronate treat-
ment, because there was no statistically significant differ-
ence to changes in urinary NTX level between patients
who continued and those who discontinued alendronate
treatment.
Previously, the main factors contributing to the
discontinuation of alendronate treatment in postmeno-
pausal women with osteoporosis were adverse gastroin-
testinal events and age.15,16,21 The factors contributing
to discontinuation in our study were: side effects (diar-
rhea [n = 1], gastric symptoms [n = 9], and inflamma-
tion of the mouth [n = 1]) or non-compliance (n = 3),
with gastrointestinal adverse events being the most
significant. The results of logistic regression analysis
showed that the number of prevalent vertebral frac-
tures was a significant factor that influenced the dis-
continuation of alendronate treatment. Contrary to our
expectations, the mean number of prevalent vertebral
fractures was greater in patients who continued alen-
dronate treatment than those who discontinued the
treatment. However, the threshold number for verte-
bral fractures remains uncertain. Finally, a family his-
tory of osteoporotic fractures could influence the level
of treatment adherence, although this factor was not
included in the analysis.
Recently, a higher incidence of esophageal hiatal
hernia and gastroesophageal reflux disease has been re-
ported in postmenopausal women. The presence and
severity of vertebral fractures are also associated with
the presence of esophageal hiatal hernia in postmeno-
pausal women,22 and the prevalence of gastroesopha-
geal reflux is increased in elderly women.23 We surmise
that because women with multiple vertebral fractures
might often have gastroesophageal problems, this may
contribute to difficulty in taking medicine and low
adherence. It could be that elderly, osteoporotic women
had been suffering from severe osteoporosis for a long
time, and that the number of these patients’ prevalent
vertebral fractures was a significant factor in their deci-
sion to discontinue alendronate treatment.
Intravenous bisphosphonates such as zoledronate
and ibandronate may be useful in preventing adverse
gastrointestinal events and to improve compliance
because of their convenient dosing regimens. There-
fore, these agents could be first line drugs in patients
who have a risk of adverse gastrointestinal events or
non-compliance with oral bisphosphonates treatment.
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The limitations of this research include the fact that
this trial was carried out by a GP at a local outpatient
clinic so the study was not a placebo-controlled trial
but a cohort study. Second, the sample size was deter-
mined by the number of subjects available rather than
on the basis of the sample size required for statistical
validity, and may have been too small to draw valid
conclusions. Therefore, our results should not be extra-
polated to the population at large. However, we believe
that the significant results from our research should
be made available to Japanese GPs working in local
outpatient clinics because the patient characteristics
and methods of monitoring and follow-up may be
similar to ours. Further studies are needed to confirm
our results.
In conclusion, this study showed that alendronate
treatment decreased urinary NTX and serum ALP
levels, and maintained metacarpal BMD in post-
menopausal Japanese women with osteoporosis. The
patients adhered well to alendronate treatment in our
clinic. The number of prevalent vertebral fractures
was an important factor affecting the discontinuation
of alendronate treatment due to side effects and 
non-compliance.
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